CSL (CSLLY) Debt-to-EBITDA : 2.00 (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is CSL Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CSL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,420 Mil. CSL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10,687 Mil. CSL's annualized EBITDA for the quarter that ended in Dec. 2023 was $6,068 Mil. CSL's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CSL's Debt-to-EBITDA or its related term are showing as below:

CSLLY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.02 Med: 1.67 Max: 3.13
Current: 2.76

During the past 13 years, the highest Debt-to-EBITDA Ratio of CSL was 3.13. The lowest was 1.02. And the median was 1.67.

CSLLY's Debt-to-EBITDA is ranked worse than
63.31% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs CSLLY: 2.76

CSL Debt-to-EBITDA Historical Data

The historical data trend for CSL's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Debt-to-EBITDA Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-EBITDA

Get a 7-Day Free Trial

1.61

1.91

1.60

2.79

3.13

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															1.12	4.90	2.38	4.52	2.00

Competitive Comparison of CSL's Debt-to-EBITDA

For the Biotechnology subindustry, CSL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSL's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CSL's Debt-to-EBITDA falls into.

CSL Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CSL's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1055	+	11172)	/	3902
	=	3.13

CSL's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1420	+	10687)	/	6068
	=	2.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

CSL (OTCPK:CSLLY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

CSL Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CSL's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CSLLY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

CMXHF:USA CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.